Perampanel and levetiracetam both control SeLECTS with minor sleep differences
This small pilot cohort offers preliminary, exploratory comparative data on how two anti-seizure medications differ in objective sleep architecture in children with self-limited epilepsy with centrotemporal spikes.
📅 Journal publication: Nov 2026(online Aug 8, 2026)·Last updated: Aug 13, 2026
Self-limited epilepsy with centrotemporal spikes (SeLECTS) often affects sleep, impacting overall management in children. Both levetiracetam (LEV) and perampanel (PER) showed effective seizure control; PER may improve sleep architecture, reducing light sleep and awakenings. While both treatments are viable, PER may offer additional sleep benefits. Longer studies are needed for conclusive evidence. LEV and PER effectively control seizures in SeLECTS; PER shows potential sleep benefits.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Yan L, Xie L, Li T, Chen J, Jiang L
Citation:Yan L, Xie L, Li T, et al. Efficacy and sleep impact of perampanel versus levetiracetam monotherapy for SeLECTS: A pilot prospective cohort study. Epilepsy & behavior : E&B. 2026;184:111228. doi:10.1016/j.yebeh.2026.111228